Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. ulcer healing
Show results for
Products
Applications

Companies

News
Articles
Videos

Refine by
Date

  • Older

Ulcer Healing Articles & Analysis

13 news found

Hemostemix’s Social Media for Investors and Florida’s No-Option Patients

Hemostemix’s Social Media for Investors and Florida’s No-Option Patients

Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...

ByHemostemix Inc.


Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis

The episodes, known as Raynaud's phenomenon, are often followed by very painful and difficult-to-heal digital ulcers (ulcers of the fingers and toes). Current pharmaceutical treatments are often ineffective and may have safety and tolerability issues. ...

ByGesynta Pharma AB


Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations

Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix Announces Rick Groome as Special Advisor to the CEO

Hemostemix Announces Rick Groome as Special Advisor to the CEO

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix Announces Settlement Agreement

Hemostemix Announces Settlement Agreement

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Preventing Wound Infections and Complications at Urgent Care

Preventing Wound Infections and Complications at Urgent Care

Urgent care providers are responsible for providing treatment that promotes healing and helps prevent wound infection. New wound closure options like the microMend bandage may help. ...

ByKitoTech Medical, Inc.


Hemostemix Announces Closing of UNIT Private Placement

Hemostemix Announces Closing of UNIT Private Placement

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics

Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix to combine ACP-01 with Dr. James Shapiro’s Islet Cells to treat Type 1 Diabetes

Hemostemix to combine ACP-01 with Dr. James Shapiro’s Islet Cells to treat Type 1 Diabetes

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix Announces Soft Lock of Database as Source Document Verification Completed

Hemostemix Announces Soft Lock of Database as Source Document Verification Completed

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of ...

ByHemostemix Inc.


Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248

In the first stage, attacks of Raynaud's phenomenon occur, often followed by painful and difficult-to-heal digital ulcers (ulcers of the fingers and toes). The lungs, kidneys and heart can also be severely impaired as a result of the inflammation and damage in the microvessels. ...

ByGesynta Pharma AB


2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies

2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies

Additionally, a high-quality paper published on April 19, 2021 in the journal Diabetic Medicine, entitled Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis (https://onlinelibrary.wiley.com/doi/10.1111/dme.14585), from the team headed by Professor Golledge at the independent Queensland Research Centre for Peripheral Vascular Disease ...

ByAdvanced Oxygen Therapy Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT